# Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC

> **NCT07641023** · PHASE1,PHASE2 · RECRUITING · sponsor: **Beijing Biotech** · enrollment: 60 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer
- Advanced/Metastatic

## Interventions

- **BIOLOGICAL:** Dual-target CAR-NK cells
- **DRUG:** Lymphodepleting chemotherapy
- **OTHER:** Supportive care

## Key facts

- **NCT ID:** NCT07641023
- **Lead sponsor:** Beijing Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-02
- **Primary completion:** 2027-03-14
- **Final completion:** 2028-06-17
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07641023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07641023, "Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07641023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*